Tauroursodeoxycholic Acid Reduces Neuroinflammation but Does Not Support Long Term Functional Recovery of Rats with...

Area of Science:

• Neuroscience
• Regenerative Medicine
• Pharmacology

Background:

• Spinal cord injury (SCI) leads to cell death, limiting the efficacy of cell-based therapies.
• Bone marrow-derived stromal cells (bmSC) are being investigated for SCI treatment.
• Tauroursodeoxycholic acid (TUDCA), a bile acid, exhibits cytoprotective effects against oxidative stress and inflammation.

Purpose of the Study:

• To investigate the therapeutic potential of TUDCA in a rat model of SCI.
• To evaluate TUDCA as a combinatorial treatment with human bmSC for SCI.

Main Methods:

• A T9 spinal cord contusion model was established in rats.
• Animals received intraperitoneal injections of TUDCA alone or in combination with bmSC.
• Motor function recovery, bladder control, and spinal cord tissue were assessed over six weeks.

Main Results:

• TUDCA demonstrated anti-inflammatory effects and transient improvements in bladder control and motor function.
• These benefits were not sustained, with no significant differences observed between TUDCA-treated and vehicle groups after six weeks.
• Combined TUDCA and bmSC treatment did not yield superior outcomes compared to bmSC treatment alone.

Conclusions:

• TUDCA alone does not provide sustained therapeutic benefits for SCI in this rat model.
• Combinatorial therapy with TUDCA and bmSC does not enhance the efficacy of bmSC treatment for SCI.
• Current data do not support the use of TUDCA for treating spinal cord injury.